{
    "clinical_study": {
        "@rank": "154740", 
        "acronym": "TRUTH", 
        "arm_group": {
            "arm_group_label": "Stealth 360\u00b0\u00ae OAS", 
            "arm_group_type": "Other", 
            "description": "Cardiovascular Systems Inc.'s Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)"
        }, 
        "brief_summary": {
            "textblock": "IVUS imaging will be utilized to assess performance of the Sponsor's Orbital Atherectomy\n      System (OAS) followed by adjunctive balloon angioplasty (BA) in patients who have\n      symptomatic peripheral artery disease (PAD) occurring in the Superficial Femoral Artery\n      (SFA), Popliteal (POP),and/or Tibioperoneal Trunk (TPT)."
        }, 
        "brief_title": "Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Artery Disease", 
            "PAD", 
            "Claudication", 
            "Peripheral Vascular Disease", 
            "PVD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Vascular Diseases", 
                "Peripheral Vascular Diseases", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a prospective, single-arm (non-randomized), post-market study which will\n      enroll up to 25 subjects.  IVUS imaging and angiography will be used to assess procedural\n      outcomes in patients who have symptomatic peripheral artery disease who are treated with the\n      Sponsor's OAS and adjunctive balloon angioplasty.  An independent IVUS Core Lab will be used\n      to provide adjudicated analyses for IVUS outcomes.  In clinic follow-up visits will be\n      performed to one year (2 weeks, 6 months, 12 months)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject's age \u2265 18 years\n\n          -  Subject is an acceptable candidate for percutaneous intervention using the Sponsor's\n             OAS in accordance with its labeled indications and instructions for use\n\n          -  Target lesion(s) located in a superficial femoral artery (SFA), popliteal (POP) or\n             tibioperoneal trunk (TPT)\n\n          -  Tight lesions (>70% stenosis)\n\n          -  Lesions less than 110 mm in length\n\n          -  Artery with the vessel < 6.5 mm in diameter\n\n          -  Subject is willing and able to sign an approved informed consent form\n\n          -  Subject is willing and able to attend follow-up visits\n\n        Exclusion Criteria:\n\n          -  Uncontrolled allergy to nitinol, stainless-steel or other stent materials or to\n             contrast agent\n\n          -  Unable to take appropriate antiplatelet therapy\n\n          -  Subject has no distal run-off\n\n          -  Interventional treatment is intended for in-stent restenosis at the peripheral\n             vascular site\n\n          -  Subject has history of coagulopathy or hypercoagulable disorder, is undergoing\n             hemodialysis or has impaired renal function (Cr > 2.5 mg/dl) at the time of treatment\n\n          -  Female subject who is pregnant or nursing a child\n\n          -  Intended interventional treatment includes planned laser, brachytherapy or\n             atherectomy procedure other than the Sponsor's OAS"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938391", 
            "org_study_id": "TRUTH"
        }, 
        "intervention": {
            "arm_group_label": "Stealth 360\u00b0\u00ae OAS", 
            "description": "Cardiovascular Systems Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)", 
            "intervention_name": "Stealth 360\u00b0\u00ae OAS", 
            "intervention_type": "Device", 
            "other_name": [
                "Orbital Atherectomy System", 
                "OAS"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peripheral Artery Disease", 
            "PAD", 
            "Claudication", 
            "Peripheral Vascular Disease", 
            "PVD", 
            "Orbital Atherectomy", 
            "Balloon Angioplasty", 
            "Intravascular Ultrasound (IVUS)"
        ], 
        "lastchanged_date": "September 9, 2013", 
        "location": {
            "contact": {
                "last_name": "Anvar Babaev, MD, PhD", 
                "phone": "212-263-5656"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "NYU School of Medicine"
            }, 
            "investigator": {
                "last_name": "Anvar Babaev, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal (TRUTH Study)", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MAE's are defined for the study as rates of death, major unplanned amputation (above the ankle) of the index limb, and clinically-driven target lesion revascularization (TLR).", 
            "measure": "Rate of Major Adverse Events (MAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Procedure to one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938391"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cardiovascular Systems Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiovascular Systems Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}